Skip to main content
. 2016 Mar 17;7(23):33744–33764. doi: 10.18632/oncotarget.8164

Figure 4. Assessment of DKO CD8 T cell priming in vivo.

Figure 4

CD45.1+ WT or DKO OT1 T cells were adoptively transferred into recipients (CD45.1+CD45.2+), which were subsequently immunized with SIINFEKL peptide emulsified in the CFA at inguina by hypodermic injection. Donor-derived OT1 T cells in inguinal dLNs harvested 12 hours after immunization were analyzed by flow cytometry. a. Representative dot plots; gated CD45.1+CD45.2− cells represent donor-derived OT1 T cells. b. Mean ± SEM of percentages of donor-derived OT1 T cells (n = 5). c. Donor OT1 T cell numbers (mean ± SEM) in dLNs (n = 5). d.-e. Expression of indicated chemokine receptors in donor-derived OT1 T cells. d. Representative overlaid histograms. e. gMFI (mean ± SEM) of indicated chemokine receptors in gated WT or DKO OT1 T cells (N = 5). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Student's t test). Data shown are representative or calculated from two independent experiments.